These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 29793956)

  • 41. Oncolytic herpes simplex virus and immunotherapy.
    Ma W; He H; Wang H
    BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
    Todo T; Martuza RL; Rabkin SD; Johnson PA
    Proc Natl Acad Sci U S A; 2001 May; 98(11):6396-401. PubMed ID: 11353831
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
    Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
    Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
    Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
    J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
    Samoto K; Perng GC; Ehtesham M; Liu Y; Wechsler SL; Nesburn AB; Black KL; Yu JS
    Cancer Gene Ther; 2001 Apr; 8(4):269-77. PubMed ID: 11393279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.
    Jackson JD; McMorris AM; Roth JC; Coleman JM; Whitley RJ; Gillespie GY; Carroll SL; Markert JM; Cassady KA
    Gene Ther; 2014 Nov; 21(11):984-90. PubMed ID: 25119379
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Herpes simplex virus 2 ICP34.5 confers neurovirulence by regulating the type I interferon response.
    Davis KL; Korom M; Morrison LA
    Virology; 2014 Nov; 468-470():330-339. PubMed ID: 25238641
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High accumulation of Mx2 renders limited multiplication of oncolytic herpes simplex virus-1 in human tumor cells.
    Ren Y; Chen M; Wu G; Ji D; Zhou GG; Ren PG; Fu W
    Sci Rep; 2021 Oct; 11(1):21227. PubMed ID: 34707174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
    Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
    Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
    Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
    Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3.
    Delwar ZM; Kuo Y; Wen YH; Rennie PS; Jia W
    Cancer Res; 2018 Feb; 78(3):718-730. PubMed ID: 29118089
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhanced IL-12 transgene expression improves oncolytic viroimmunotherapy.
    Kim Y; Saini U; Kim D; Hernandez-Aguirre I; Hedberg J; Martin A; Mo X; Cripe TP; Markert J; Cassady KA; Dhital R
    Front Immunol; 2024; 15():1375413. PubMed ID: 38895115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based Vectors.
    Abdoli Sh; Roohvand F; Teimoori-Toolabi L; Shokrgozar MA; Bahrololoumi M; Azadmanesh K
    Iran Biomed J; 2017 Jul; 21(4):206-17. PubMed ID: 28525954
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
    Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
    Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
    Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
    Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1.
    Gaston DC; Odom CI; Li L; Markert JM; Roth JC; Cassady KA; Whitley RJ; Parker JN
    PLoS One; 2013; 8(11):e81768. PubMed ID: 24312353
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma.
    Takaoka H; Takahashi G; Ogawa F; Imai T; Iwai S; Yura Y
    Virol J; 2011 Jun; 8():294. PubMed ID: 21663640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of Herpes Simplex Virus 1 γ34.5 in the Regulation of IRF3 Signaling.
    Manivanh R; Mehrbach J; Knipe DM; Leib DA
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28904192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Zika virus has oncolytic activity against glioblastoma stem cells.
    Zhu Z; Gorman MJ; McKenzie LD; Chai JN; Hubert CG; Prager BC; Fernandez E; Richner JM; Zhang R; Shan C; Tycksen E; Wang X; Shi PY; Diamond MS; Rich JN; Chheda MG
    J Exp Med; 2017 Oct; 214(10):2843-2857. PubMed ID: 28874392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.
    Hua L; Wakimoto H
    Expert Opin Biol Ther; 2019 Aug; 19(8):845-854. PubMed ID: 31046478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.